Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 257 entries
Sorted by: Best Match Show Resources per page
Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder.

Prostate international

Lee SH, Lee JY.
PMID: 25032191
Prostate Int. 2014;2(2):43-9. doi: 10.12954/PI.14045. Epub 2014 Jun 30.

Lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH) are highly prevalent in older men. The storage subcategory of LUTS is synonymous with overactive bladder (OAB) syndrome, which is an empirical diagnosis. Traditionally, alpha-blockers are widely prescribed to...

Cite
Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014;2(2):43-9doi: 10.12954/PI.14045.
Lee, S. H., & Lee, J. Y. (2014). Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate international, 2(2), 43-9. https://doi.org/10.12954/PI.14045
Lee, Seung Hwan, and Lee, Ji Youl. "Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder." Prostate international vol. 2,2 (2014): 43-9. doi: https://doi.org/10.12954/PI.14045
Lee SH, Lee JY. Current role of treatment in men with lower urinary tract symptoms combined with overactive bladder. Prostate Int. 2014;2(2):43-9. doi: 10.12954/PI.14045. Epub 2014 Jun 30. PMID: 25032191; PMCID: PMC4099395.
Copy Download .nbib Format: NLM
Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring.

Prostate international

Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH.
PMID: 25032193
Prostate Int. 2014;2(2):76-81. doi: 10.12954/PI.14044. Epub 2014 Jun 30.

PURPOSE: We compared oncological outcomes according to tumor volume (TV) thresholds defining both classical and updated insignificant prostate cancer (IPC), since the TV threshold can be used as clinical parameter for active surveillance.METHODS: Between 2001 and 2012, we retrospectively...

Cite
Lee DH, Koo KC, Lee SH, et al. Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring. Prostate Int. 2014;2(2):76-81doi: 10.12954/PI.14044.
Lee, D. H., Koo, K. C., Lee, S. H., Rha, K. H., Choi, Y. D., Hong, S. J., & Chung, B. H. (2014). Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring. Prostate international, 2(2), 76-81. https://doi.org/10.12954/PI.14044
Lee, Dong Hoon, et al. "Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring." Prostate international vol. 2,2 (2014): 76-81. doi: https://doi.org/10.12954/PI.14044
Lee DH, Koo KC, Lee SH, Rha KH, Choi YD, Hong SJ, Chung BH. Analysis of different tumor volume thresholds of insignificant prostate cancer and their implications for active surveillance patient selection and monitoring. Prostate Int. 2014;2(2):76-81. doi: 10.12954/PI.14044. Epub 2014 Jun 30. PMID: 25032193; PMCID: PMC4099398.
Copy Download .nbib Format: NLM
Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins.

Prostate international

Furuya Y, Sekine Y, Kato H, Miyazawa Y, Koike H, Suzuki K.
PMID: 27358845
Prostate Int. 2016 Jun;4(2):56-60. doi: 10.1016/j.prnil.2016.02.003. Epub 2016 Mar 04.

BACKGROUND: There are some reports about the antitumor effects of statins in these days. Statins decrease the level of cholesterol in the blood by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Inhibition of this enzyme decreases intracellular cholesterol synthesis. Thus, the expression...

Cite
Furuya Y, Sekine Y, Kato H, et al. Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate Int. 2016;4(2):56-60doi: 10.1016/j.prnil.2016.02.003.
Furuya, Y., Sekine, Y., Kato, H., Miyazawa, Y., Koike, H., & Suzuki, K. (2016). Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate international, 4(2), 56-60. https://doi.org/10.1016/j.prnil.2016.02.003
Furuya, Yosuke, et al. "Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins." Prostate international vol. 4,2 (2016): 56-60. doi: https://doi.org/10.1016/j.prnil.2016.02.003
Furuya Y, Sekine Y, Kato H, Miyazawa Y, Koike H, Suzuki K. Low-density lipoprotein receptors play an important role in the inhibition of prostate cancer cell proliferation by statins. Prostate Int. 2016 Jun;4(2):56-60. doi: 10.1016/j.prnil.2016.02.003. Epub 2016 Mar 04. PMID: 27358845; PMCID: PMC4916060.
Copy Download .nbib Format: NLM
Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer.

Prostate international

Kongseang C, Attawettayanon W, Kanchanawanichkul W, Pripatnanont C.
PMID: 28352622
Prostate Int. 2017 Mar;5(1):35-38. doi: 10.1016/j.prnil.2017.01.004. Epub 2017 Feb 07.

BACKGROUND: The purpose of this study was to identify the predictive factors for the efficacy of androgen deprivation therapy (ADT) in men with hormone-sensitive prostate cancer (PC) with or without distant metastasis.METHODS: A retrospective review of PC patients was...

Cite
Kongseang C, Attawettayanon W, Kanchanawanichkul W, et al. Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer. Prostate Int. 2017;5(1):35-38doi: 10.1016/j.prnil.2017.01.004.
Kongseang, C., Attawettayanon, W., Kanchanawanichkul, W., & Pripatnanont, C. (2017). Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer. Prostate international, 5(1), 35-38. https://doi.org/10.1016/j.prnil.2017.01.004
Kongseang, Chaiyut, et al. "Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer." Prostate international vol. 5,1 (2017): 35-38. doi: https://doi.org/10.1016/j.prnil.2017.01.004
Kongseang C, Attawettayanon W, Kanchanawanichkul W, Pripatnanont C. Predictive factor of androgen deprivation therapy for patients with advanced stage prostate cancer. Prostate Int. 2017 Mar;5(1):35-38. doi: 10.1016/j.prnil.2017.01.004. Epub 2017 Feb 07. PMID: 28352622; PMCID: PMC5357969.
Copy Download .nbib Format: NLM
Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand.

Prostate international

Lojanapiwat B, Pripatnanont C, Choonhaklai V, Soontornpun S, Sriplakich S, Leewansangtong S, Santi-Ngamkun A, Opanuraks J, Kongcharoensombat W, Na-Songkla B, Raksakul W, Predanon C.
PMID: 28352616
Prostate Int. 2017 Mar;5(1):1-7. doi: 10.1016/j.prnil.2017.01.002. Epub 2017 Jan 11.

Treatment options for castration-resistant prostate cancer (CRPC) are available, but clear instructions for the selection of appropriate treatment are lacking. A meeting of urology experts based in Thailand was convened with the following objectives: (1) to reach a consensus...

Cite
Lojanapiwat B, Pripatnanont C, Choonhaklai V, et al. Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand. Prostate Int. 2017;5(1):1-7doi: 10.1016/j.prnil.2017.01.002.
Lojanapiwat, B., Pripatnanont, C., Choonhaklai, V., Soontornpun, S., Sriplakich, S., Leewansangtong, S., Santi-Ngamkun, A., Opanuraks, J., Kongcharoensombat, W., Na-Songkla, B., Raksakul, W., & Predanon, C. (2017). Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand. Prostate international, 5(1), 1-7. https://doi.org/10.1016/j.prnil.2017.01.002
Lojanapiwat, Bannakij, et al. "Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand." Prostate international vol. 5,1 (2017): 1-7. doi: https://doi.org/10.1016/j.prnil.2017.01.002
Lojanapiwat B, Pripatnanont C, Choonhaklai V, Soontornpun S, Sriplakich S, Leewansangtong S, Santi-Ngamkun A, Opanuraks J, Kongcharoensombat W, Na-Songkla B, Raksakul W, Predanon C. Management of metastatic castration-resistant prostate cancer: Insights from urology experts in Thailand. Prostate Int. 2017 Mar;5(1):1-7. doi: 10.1016/j.prnil.2017.01.002. Epub 2017 Jan 11. PMID: 28352616; PMCID: PMC5357973.
Copy Download .nbib Format: NLM
Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients.

Prostate international

Ng SP, Duchesne G, Tai KH, Foroudi F, Kothari G, Williams S.
PMID: 28352617
Prostate Int. 2017 Mar;5(1):8-12. doi: 10.1016/j.prnil.2016.12.001. Epub 2016 Dec 18.

BACKGROUND: Prostate cancer management involves a balance between the risks of cancer death against those from other causes. To evaluate the performance of several comorbidity indices in predicting comorbid death in a prostate cancer radiotherapy cohort.METHODS: 2,131 men with...

Cite
Ng SP, Duchesne G, Tai KH, et al. Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate Int. 2016;5(1):8-12doi: 10.1016/j.prnil.2016.12.001.
Ng, S. P., Duchesne, G., Tai, K. H., Foroudi, F., Kothari, G., & Williams, S. (2017). Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate international, 5(1), 8-12. https://doi.org/10.1016/j.prnil.2016.12.001
Ng, Sweet Ping, et al. "Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients." Prostate international vol. 5,1 (2017): 8-12. doi: https://doi.org/10.1016/j.prnil.2016.12.001
Ng SP, Duchesne G, Tai KH, Foroudi F, Kothari G, Williams S. Support for the use of objective comorbidity indices in the assessment of noncancer death risk in prostate cancer patients. Prostate Int. 2017 Mar;5(1):8-12. doi: 10.1016/j.prnil.2016.12.001. Epub 2016 Dec 18. PMID: 28352617; PMCID: PMC5357856.
Copy Download .nbib Format: NLM
Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy.

Prostate international

Kang M, Lee S, Oh JJ, Hong SK, Lee SE, Byun SS.
PMID: 26779458
Prostate Int. 2015 Dec;3(4):123-6. doi: 10.1016/j.prnil.2015.10.015. Epub 2015 Oct 20.

BACKGROUND: The aim of this study was to investigate the effects of surgical castration, particularly delaying the time to entrance of systemic chemotherapy, in castration-resistant prostate cancer (CRPC) patients who were refractory to initial combination androgen deprivation therapy.MATERIALS AND...

Cite
Kang M, Lee S, Oh JJ, et al. Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate Int. 2015;3(4):123-6doi: 10.1016/j.prnil.2015.10.015.
Kang, M., Lee, S., Oh, J. J., Hong, S. K., Lee, S. E., & Byun, S. S. (2015). Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate international, 3(4), 123-6. https://doi.org/10.1016/j.prnil.2015.10.015
Kang, Minyong, et al. "Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy." Prostate international vol. 3,4 (2015): 123-6. doi: https://doi.org/10.1016/j.prnil.2015.10.015
Kang M, Lee S, Oh JJ, Hong SK, Lee SE, Byun SS. Surgical castration efficiently delays the time of starting a systemic chemotherapy in castration-resistant prostate cancer patients refractory to initial androgen-deprivation therapy. Prostate Int. 2015 Dec;3(4):123-6. doi: 10.1016/j.prnil.2015.10.015. Epub 2015 Oct 20. PMID: 26779458; PMCID: PMC4685208.
Copy Download .nbib Format: NLM
Prostate International, an international academic forum on prostate diseases.

Prostate international

Kim CS.
PMID: 24223393
Prostate Int. 2013;1(1):1. doi: 10.12954/PI.13001.

No abstract available.

Cite
Kim CS. Prostate International, an international academic forum on prostate diseases. Prostate Int. 2013;1(1):1doi: 10.12954/PI.13001.
Kim, C. S. (2013). Prostate International, an international academic forum on prostate diseases. Prostate international, 1(1), 1. https://doi.org/10.12954/PI.13001
Kim, Choung-Soo. "Prostate International, an international academic forum on prostate diseases." Prostate international vol. 1,1 (2013): 1. doi: https://doi.org/10.12954/PI.13001
Kim CS. Prostate International, an international academic forum on prostate diseases. Prostate Int. 2013;1(1):1. doi: 10.12954/PI.13001. PMID: 24223393; PMCID: PMC3821516.
Copy Download .nbib Format: NLM
Early experience photoselective vaporisation of the prostate using the 180W lithium triborate and comparison with the 120W lithium triborate laser.

Prostate international

Campbell NA, Chung AS, Yoon PD, Thangasamy I, Woo HH.
PMID: 24223401
Prostate Int. 2013;1(1):42-5. doi: 10.12954/PI.12006. Epub 2013 Feb 04.

PURPOSE: There is a paucity of information on the clinical efficacy and safety of the photoselective vaporization (PVP) of the prostate using the 180W lithium triborate (LBO) laser. We report on initial outcomes of PVP with the 180W laser,...

Cite
Campbell NA, Chung AS, Yoon PD, et al. Early experience photoselective vaporisation of the prostate using the 180W lithium triborate and comparison with the 120W lithium triborate laser. Prostate Int. 2013;1(1):42-5doi: 10.12954/PI.12006.
Campbell, N. A., Chung, A. S., Yoon, P. D., Thangasamy, I., & Woo, H. H. (2013). Early experience photoselective vaporisation of the prostate using the 180W lithium triborate and comparison with the 120W lithium triborate laser. Prostate international, 1(1), 42-5. https://doi.org/10.12954/PI.12006
Campbell, Nicholas A, et al. "Early experience photoselective vaporisation of the prostate using the 180W lithium triborate and comparison with the 120W lithium triborate laser." Prostate international vol. 1,1 (2013): 42-5. doi: https://doi.org/10.12954/PI.12006
Campbell NA, Chung AS, Yoon PD, Thangasamy I, Woo HH. Early experience photoselective vaporisation of the prostate using the 180W lithium triborate and comparison with the 120W lithium triborate laser. Prostate Int. 2013;1(1):42-5. doi: 10.12954/PI.12006. Epub 2013 Feb 04. PMID: 24223401; PMCID: PMC3821518.
Copy Download .nbib Format: NLM
The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen.

Prostate international

Cho HJ, Shin SC, Cho JM, Kang JY, Yoo TK.
PMID: 25599076
Prostate Int. 2014 Dec;2(4):196-202. doi: 10.12954/PI.14060. Epub 2014 Dec 30.

PURPOSE: The aim of this study was to define the clinical significance of transurethral resection of the prostate (TURP) in patients with benign prostate hyperplasia (BPH) and an elevated prostate-specific antigen (PSA) level.METHODS: We retrospectively evaluated patients with BPH,...

Cite
Cho HJ, Shin SC, Cho JM, et al. The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen. Prostate Int. 2014;2(4):196-202doi: 10.12954/PI.14060.
Cho, H. J., Shin, S. C., Cho, J. M., Kang, J. Y., & Yoo, T. K. (2014). The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen. Prostate international, 2(4), 196-202. https://doi.org/10.12954/PI.14060
Cho, Hee Ju, et al. "The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen." Prostate international vol. 2,4 (2014): 196-202. doi: https://doi.org/10.12954/PI.14060
Cho HJ, Shin SC, Cho JM, Kang JY, Yoo TK. The role of transurethral resection of the prostate for patients with an elevated prostate-specific antigen. Prostate Int. 2014 Dec;2(4):196-202. doi: 10.12954/PI.14060. Epub 2014 Dec 30. PMID: 25599076; PMCID: PMC4286732.
Copy Download .nbib Format: NLM
The impact of obesity towards prostate diseases.

Prostate international

Parikesit D, Mochtar CA, Umbas R, Hamid AR.
PMID: 27014656
Prostate Int. 2016 Mar;4(1):1-6. doi: 10.1016/j.prnil.2015.08.001. Epub 2015 Nov 24.

Evidence has supported obesity as a risk factor for both benign prostate hyperplasia (BPH) and prostate cancer (PCa). Obesity causes several mechanisms including increased intra-abdominal pressure, altered endocrine status, increased sympathetic nervous activity, increased inflammation process, and oxidative stress,...

Cite
Parikesit D, Mochtar CA, Umbas R, et al. The impact of obesity towards prostate diseases. Prostate Int. 2015;4(1):1-6doi: 10.1016/j.prnil.2015.08.001.
Parikesit, D., Mochtar, C. A., Umbas, R., & Hamid, A. R. (2016). The impact of obesity towards prostate diseases. Prostate international, 4(1), 1-6. https://doi.org/10.1016/j.prnil.2015.08.001
Parikesit, Dyandra, et al. "The impact of obesity towards prostate diseases." Prostate international vol. 4,1 (2016): 1-6. doi: https://doi.org/10.1016/j.prnil.2015.08.001
Parikesit D, Mochtar CA, Umbas R, Hamid AR. The impact of obesity towards prostate diseases. Prostate Int. 2016 Mar;4(1):1-6. doi: 10.1016/j.prnil.2015.08.001. Epub 2015 Nov 24. PMID: 27014656; PMCID: PMC4789344.
Copy Download .nbib Format: NLM
Oxidative stress in prostate cancer patients: A systematic review of case control studies.

Prostate international

Oh B, Figtree G, Costa D, Eade T, Hruby G, Lim S, Elfiky A, Martine N, Rosenthal D, Clarke S, Back M.
PMID: 27689064
Prostate Int. 2016 Sep;4(3):71-87. doi: 10.1016/j.prnil.2016.05.002. Epub 2016 May 24.

BACKGROUND: Prostate cancer (PCa) is the most common cancer in men in Western countries. In-vitro and in-vivo studies suggest that oxidative stress (OS) and antioxidants play a key role in the pathogenesis of chronic diseases including PCa, which is...

Cite
Oh B, Figtree G, Costa D, et al. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016;4(3):71-87doi: 10.1016/j.prnil.2016.05.002.
Oh, B., Figtree, G., Costa, D., Eade, T., Hruby, G., Lim, S., Elfiky, A., Martine, N., Rosenthal, D., Clarke, S., & Back, M. (2016). Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate international, 4(3), 71-87. https://doi.org/10.1016/j.prnil.2016.05.002
Oh, Byeongsang, et al. "Oxidative stress in prostate cancer patients: A systematic review of case control studies." Prostate international vol. 4,3 (2016): 71-87. doi: https://doi.org/10.1016/j.prnil.2016.05.002
Oh B, Figtree G, Costa D, Eade T, Hruby G, Lim S, Elfiky A, Martine N, Rosenthal D, Clarke S, Back M. Oxidative stress in prostate cancer patients: A systematic review of case control studies. Prostate Int. 2016 Sep;4(3):71-87. doi: 10.1016/j.prnil.2016.05.002. Epub 2016 May 24. PMID: 27689064; PMCID: PMC5031904.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 257 entries